Jump to any asset
850 assets, updated daily
As of September 11, 2026, Capricor Therapeutics, Inc. (CAPR) trades at $8.30. CleaRank Financial AI rates it Hold with a fair value of $8.30, in line with the current price. Wall Street's consensus target is $26.50 across 9 analysts. RSI at 60 is in neutral territory, and the price is below its 50-day average of $11.62.
Capricor Therapeutics, Inc. (CAPR)
Capricor Therapeutics, Inc. NASDAQ
$8.30
-0.3400 (-3.94%)
Latest Price
AI Analyst Consensus
59 / 100
Capricor Therapeutics, Inc. (CAPR) is currently trading at $8.30, below its 50-day and 200-day moving averages ($11.62 and $23.42), indicating a bearish short-term trend. The company has experienced significant insider selling totaling $8.4 million in the past reporting period, with no insider purchases, signaling a lack of confidence from management. Despite these headwinds, the median Wall Street price target stands at $26.50, suggesting a potential upside of 219.3%. However, the consensus rating is 'Hold' with 6 out of 9 analysts rating the stock as such, reflecting a cautious outlook from the broader analyst community.
CAPR Price Analysis
Market Metrics
Open
$8.58
Day Range
$8.18 to $8.70
Prev Close
$8.64
Volume
2.91M
52-Week Range
$2.96 to $40.37
Market Cap
$482.55M
Peer Benchmarking
Valuation vs Sector (Healthcare)
Performance vs XLV
Sector Position Analysis
CAPR Analysis
Company's Health
2/5
AI Technical Analysis
Capricor Therapeutics (CAPR) is trading below its 50-day and 200-day moving averages ($11.62 and $23.42), indicating a bearish trend. The 50-day moving average is acting as resistance at $11.62, while the 200-day moving average is at $23.42. The Relative Strength Index (RSI) is at 60.2, which is in the bullish momentum territory, but the MACD at -0.37 suggests weakening momentum. Key support levels are not clearly defined given the limited trading history, but the current price of $8.30 is below recent moving averages. Volume on the latest trading day was 2,912,200, which is below the average volume of 4,825,770, suggesting subdued investor interest.
ProTips
- Given the significant insider selling and recent earnings miss, consider a risk-defined approach to any potential long positions in CAPR, potentially utilizing stop-losses below key technical support levels.
- The RSI is in bullish territory (60.2), but the MACD suggests weakening momentum. Monitor for a potential divergence or confirmation signal before establishing a position.
- With a median Wall Street price target of $26.50, investors may want to monitor analyst commentary and clinical trial updates closely for potential catalysts that could drive the stock towards this target.
Key Catalysts
Bearish
Significant Insider Selling
Insiders have sold a total of $8.4 million worth of Capricor Therapeutics (CAPR) stock across 24 transactions, with no reported purchases, indicating a lack of confidence from management.
Source: Insider TransactionsBearish
Recent Earnings Miss
Capricor Therapeutics (CAPR) reported an EPS of -0.70 against an estimate of -0.58 for the quarter ending August 13, 2026, a miss of 20.69%.
Source: Earnings ReportBullish
High Median Analyst Price Target
The median Wall Street price target for CAPR is $26.50, representing a potential upside of 219.3% from the current trading price of $8.30.
Source: Wall Street AnalystsNeutral
Mixed Analyst Ratings
While the price target suggests upside, the Wall Street consensus is 'Hold', with 6 out of 9 analysts rating the stock as such, reflecting a cautious stance.
Source: Wall Street AnalystsMarket Outlook
The 6-12 month outlook for Capricor Therapeutics (CAPR) is cautiously mixed. While the median Wall Street price target of $26.50 suggests significant upside potential, the current trading price below key moving averages and substantial insider selling paint a bearish near-term picture. The company's recent earnings miss further adds to the uncertainty. Key catalysts could include positive clinical trial results or regulatory approvals, which could drive the stock towards the higher end of analyst targets. Conversely, continued operational challenges, further earnings disappointments, or a lack of progress in its pipeline could lead to a retest of lower price levels, potentially towards the downside projection of $1.85 in the long range.
Key Statistics
| Market Cap | 482.55M |
|---|---|
| P/E Ratio | N/A (Negative EPS) |
| EPS (TTM) | -2.45 |
| Dividend Yield | 0.00% |
| 52 Week High | 40.37 |
| 52 Week Low | 2.96 |
Capricor Therapeutics (CAPR) exhibits a negative EPS of -2.45, making its P/E ratio mathematically negative and rendering traditional valuation metrics like P/E and PEG unreliable. The company's revenue growth is not provided, and its current market capitalization is approximately $482.6 million. The sector median P/E is 31.9 and the median ROE is 6.9%, against which CAPR's profitability metrics are not comparable due to its loss-making status. Given the lack of positive earnings and revenue growth data, the fundamental picture is challenging. The significant insider selling further raises concerns about the company's near-term financial health and prospects.
Earnings & Growth Analysis
Capricor Therapeutics (CAPR) reported a significant earnings miss in its most recent quarter ending August 13, 2026, with an actual EPS of -0.70 against an estimate of -0.58, a surprise of -20.69%. This miss was accompanied by a substantial 57.96% price increase, suggesting market reaction was driven by factors other than the earnings report itself. Prior to this, the company beat estimates in Q2 2026 but missed in Q1 2026, indicating an inconsistent earnings performance.
Key Risks
Capricor Therapeutics (CAPR) faces significant risks including substantial insider selling totaling $8.4 million, indicating a lack of confidence from management. The company is currently loss-making with a negative EPS of -2.45 and is trading below key moving averages, signaling bearish technical momentum. Also, the most recent earnings report showed a significant miss, raising concerns about operational execution and future profitability.
Technical Indicators
| RSI (14) | 60.20 |
|---|---|
| MACD | -0.37 |
| SMA 50 | 11.62 |
| SMA 200 | 23.42 |
RSI
Bullish
SMA Cross
Bearish
Price vs SMA
Bearish
MACD
Bearish
Moving averages show a lagging Death Cross (50-day: $11.62, 200-day: $23.42), price is trading below the 50-day SMA.
Market Correlations
How this stock moves relative to other assets
Based on 1 year of daily price data. Correlations may vary over different time periods.
S&P 500 (SPY)
+0.10
Weak correlation
Nasdaq 100 (QQQ)
+0.10
Weak correlation
Bitcoin (BTC)
+0.15
Weak correlation
Gold (XAU)
-0.04
Weak correlation
Check Custom Correlation
Calculating correlation...
CAPR Trade Plans
Specific entry, exit, and risk management levels
Select Your Trade Bias
Risk Tolerance
Conservative
2%
Aggressive
Portfolio Value
$
Position Size: Enter portfolio size →
Entry Strategies (click to switch)
CONSERVATIVE
$8.217
Slight discount to current
Wait for small dip
AGGRESSIVE
$8.300
At current price
Enter now if confident
Risk Management
STOP LOSS
$6.617
MAX LOSS
-19.5%
Volatility-Adjusted Stop Loss
Calculated based on RSI (60.2) and current market volatility
Profit Targets (Based on Conservative Entry)
TARGET 1
$8.464
+3% (Conservative)
+2.0% (Aggressive)
TARGET 2
$8.628
+5% (Conservative)
+4.0% (Aggressive)
TARGET 3
$8.874
+8% (Conservative)
+6.9% (Aggressive)
Consider scaling out: Take 50% profit at Target 1, 30% at Target 2, let 20% run to Target 3
Calculate Your Trade
High-Volatility Risk Disclaimer
CAPR is classified as a high-volatility asset (Daily Vol: 12.98%). Aggressive price swings can lead to rapid capital loss. Liquidity risks may prevent exiting trades at desired prices. This AI-generated analysis is for educational purposes only and is not financial advice. Generated on September 11, 2026.Growth of $10,000
A $10,000 investment in CAPR in September 2016 would be worth about $2,112 today, compared with about $35,030 for the same investment in the S&P 500 benchmark.
Compare with Another Ticker
Monte Carlo Projection (10yr)
CleaRank's 10-year Monte Carlo simulation projects that a $10,000 investment in CAPR today could grow to about $5,782 by 2036 in the base case, with a bull case near $43,866 and a bear case around $762. Projections are statistical simulations, not guarantees.
CAPR Stock Price Prediction: 2030
CleaRank's simulation projects a price near $6.67 for CAPR by 2030 in the base case, from $8.30 today (0.8x over 4 years). The downside path ends near $1.85. These are outcomes of a Monte Carlo simulation run on CAPR's historical return distribution, not price targets, and they assume no dividends are reinvested.
| Year | Downside (10th pct) | Base case | Upside (90th pct) |
|---|---|---|---|
| 2027 | $4.14 | $7.86 | $14.91 |
| 2028 | $3.01 | $7.44 | $18.41 |
| 2029 | $2.32 | $7.04 | $21.37 |
| 2030 | $1.85 | $6.67 | $24.02 |
| 2031 | $1.51 | $6.31 | $26.45 |
| 2032 | $1.24 | $5.97 | $28.71 |
| 2033 | $1.04 | $5.66 | $30.82 |
| 2034 | $0.8742 | $5.35 | $32.80 |
| 2035 | $0.7414 | $5.07 | $34.66 |
| 2036 | $0.6326 | $4.80 | $36.41 |
Method: 10,000 simulated price paths using CAPR's historical volatility and drift, re-run daily. The base case is the median path; the two outer columns are the 10th and 90th percentile outcomes, which widen with time because uncertainty compounds. Simulations are not guarantees, and past volatility does not predict future returns. This is analysis, not investment advice.
People Also Watch
CAPR Insider Trading Analysis
Bought
None
No open-market buys
Sold
$8.4M
10 Transactions
Insiders
5
Active Traders
Avg Transaction
$836.6K
Moderate size
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Apr 1, 2026 | SABAR KARIMAH ES
Director
|
Sell | 115.0K | $3.5M |
| May 1, 2026 | KRASNEY KAREN
General Counsel
|
Sell | 25.0K | $792.5K |
| May 1, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Sell | 25.0K | $792.5K |
| Mar 31, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Sell | 25.0K | $753.2K |
| Mar 31, 2026 | KRASNEY KAREN
General Counsel
|
Sell | 25.0K | $752.9K |
| Jun 25, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Sell | 24.1K | $732.2K |
| Jun 25, 2026 | KRASNEY KAREN
General Counsel
|
Sell | 24.1K | $732.2K |
| Apr 2, 2026 | SABAR KARIMAH ES
Director
|
Sell | 7.5K | $240.9K |
| Jun 24, 2026 | BERGMANN ANTHONY
Chief Financial Officer
|
Sell | 900 | $27.0K |
| Jun 24, 2026 | KRASNEY KAREN
General Counsel
|
Sell | 900 | $27.0K |
Page 1 of 1
Frequently Asked Questions
Is Capricor Therapeutics (CAPR) stock a buy?
Capricor Therapeutics (CAPR) is currently rated a 'Hold' by Wall Street analysts, with a consensus score of 61 out of 100. While the median price target of $26.50 suggests significant upside potential from the current $8.30, substantial insider selling and a recent earnings miss present considerable risks.
What is Capricor Therapeutics' (CAPR) price target?
The median analyst price target for Capricor Therapeutics (CAPR) is $26.50, with a high of $54.00 and a low of $7.00. This median target represents a potential upside of 219.3% from the current stock price of $8.30.
What are the biggest risks for Capricor Therapeutics (CAPR)?
The primary risks for Capricor Therapeutics (CAPR) include significant insider selling totaling $8.4 million, a negative EPS of -2.45, and trading below key moving averages. The company also recently reported a substantial earnings miss, raising concerns about its operational performance.
How is Capricor Therapeutics' (CAPR) recent earnings performance?
Capricor Therapeutics (CAPR) recently reported an earnings miss for the quarter ending August 13, 2026, with EPS of -0.70 against an estimate of -0.58. This followed a pattern of inconsistent earnings reports, with a beat in Q2 2026 and a miss in Q1 2026.
What is the technical outlook for Capricor Therapeutics (CAPR)?
Technically, Capricor Therapeutics (CAPR) is in a bearish trend, trading below its 50-day and 200-day moving averages ($11.62 and $23.42). While the RSI shows bullish momentum, the MACD indicates weakening momentum, and volume is below average.
What is Capricor Therapeutics' (CAPR) revenue growth outlook?
However, Wall Street estimates project next year's revenue to be approximately $56.5 million, with a significant year-over-year growth of +244.00%, though this average is skewed by outlier estimates.
How does Capricor Therapeutics (CAPR) compare to its sector averages?
Capricor Therapeutics (CAPR) operates in the Healthcare sector. While sector averages show a median P/E of -3.39 and revenue growth of 8.1%, CAPR's P/E is not applicable due to negative EPS, and its revenue growth is not provided, indicating it is not currently comparable on these metrics.
What is Capricor Therapeutics' (CAPR) stock price prediction for 2030?
Based on Monte Carlo simulations, Capricor Therapeutics' (CAPR) projected base case price for 2030 is $6.67, with a downside projection of $1.85 and an upside projection of $24.02. These are statistical simulation outcomes, not guaranteed price targets.